BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Diabetes mellitus
,
Embryo
,
Early pregnancy factor
,
Fenofibrate
,
rs2300478
,
IL1A
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
ERK inhibitor
Summary
General Info
Curated Studies
Most Correlated Studies
Tendon stem-progenitor cells from patellar tendon injury model treated with ERK inhibitor U0126
Rhabdomyosarcoma RD cells with siRNA-induced NRAS knockdown or treated with ERK inhibitor SCH772984
Mouse chondrocytes treated with inhibitors of PI3K, histone deacetylase, and Mek/ERK pathway
MDCK cells treated with hepatocyte growth factor and MAPK ERK pathway inhibitors
Melanoma A375P cell line treated with ERK dimerization inhibitor, either DEL22379 or SCH772984
Explore Curated Studies Results
Literature
Most Relevant Literature
A patent review of MAPK inhibitors (2018 - present).
Identification of tetracycline combinations as EphB1 tyrosine kinase inhibitors for treatment of neu…
Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic …
Design, Synthesis, and Molecular Docking of Novel Miscellaneous Chalcones as p38α Mitogen-Activated …
The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein k…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies
Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ER…
A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumo…
Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Targeted PARP or MEK/ERK Inhibition in Patients With Pancreatic Cancer
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ